The ₹210.00 crore Veegaland Developers initial public offering (IPO) entered its final day of public subscription today, September 15, 2026, with a price band of ₹130 to ₹140 per share. As of 10:55 A.M on the third day of bidding, the issue had been subscribed 2.67 times.
The basis of allotment is expected to be finalised on September 16, 2026, while the shares are tentatively scheduled to be listed on the NSE and BSE on September 18, 2026.
The expected IPO schedule is as follows:
|
Event |
Date |
|
Subscription Opening Date |
10 September 2026 |
|
Subscription Closing Date |
15 September 2026 |
|
Basis of Allotment Date |
16 September 2026 |
|
Refund Initiation Date |
17 September 2026 |
|
Credit of Shares |
17 September 2026 |
|
Listing on BSE and NSE |
18 September 2026 |
Note: The allotment and listing dates are tentative and may be revised.
Explore other Upcoming IPOs on BSE and NSE.
[September 15, 2026, 10:55 A.M.]
|
Category |
Subscription (x) |
|
Qualified Institutional Buyers (QIBs) |
0.45x |
|
Non-Institutional Investors (NIIs) |
3.49x |
|
Retail Individual Investors (RIIs) |
3.58x |
|
Total |
2.67x |
The company intends to utilise the net proceeds from the fresh issue towards:
Incorporated in 2007, Veegaland Developers Limited is a Kerala-based real estate developer focused on residential and mixed-use projects. The company, part of the V-Guard Group, develops housing projects aimed at serving homebuyers across different segments.
Its portfolio includes apartments, villas, and integrated residential communities. As of June 30, 2026, Veegaland Developers had completed 10 projects, with 12 projects under development and another 3 projects in the pipeline. The company had 127 full-time employees as of the same date.
|
Particulars |
FY26 (in ₹ crore) |
FY25 (in ₹ crore) |
FY24 (in ₹ crore) |
|
Revenue from operations |
250.98 |
192.38 |
110.77 |
|
EBITDA |
42.64 |
33.77 |
16.72 |
|
Profit After Tax (PAT) |
26.62 |
20.43 |
7.88 |
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here